- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Fut8 Sugar coating immuno oncology
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel therapy for drug-resistant cancers
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Selective JAK inhibition: mimicking SOCS activity
- Targeting minor class splicing
- Treating Epstein-Barr virus associated malignancies
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Marnie Blewitt
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Bob Anderson
- Dr Brad Sleebs
- Dr Diana Hansen
- Dr Drew Berry
- Dr Emma Josefsson
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Hélène Jousset Sabroux
- Dr Ian Majewski
- Dr Ian Street
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Misty Jenkins
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rhys Allan
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Ms Samantha Ludolf
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jason Tye-Din
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- 6 cysteine proteins key mediators between malaria parasites and human host
- A balancing act of immunity: autoimmunity versus malignancies
- Activating https://www.wehi.edu.au/node/add/individual-student-research-page#Parkin to treat Parkinson’s disease
- Analysing single cell technologies to understand breast cancer
- Bioinformatics methods for detecting and making sense of somatic genomic rearrangements
- Characterising new regulators in inflammatory signalling pathways
- Computational melanoma genomics
- Control of human lymphocyte cell expansion in complex immune diseases
- Deciphering biophysical changes in red blood cell membrane during malaria parasite infection
- Deciphering the signalling functions of pseudokinases
- Deep profiling of blood cancers during targeted therapy
- Determining the mechanism of type I cytokine receptor triggering
- Differential expression analysis of RNA-seq using multivariate variance modelling
- Discovering new genetic causes of primary antibody deficiencies
- Discovery of novel drug combinations for the treatment of bowel cancer
- Drug targets and compounds that block growth of malaria parasites
- Effects of nutrition on immunity and infection in Asia and Africa
- Enabling deubiquitinase drug discovery
- Epigenetic drivers of immune cell function
- Epigenetic regulation of systemic iron homeostasis
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Fatal attraction: how apoptotic pore assembly is governed during mitochondrial cell death
- Genomic instability and the immune microenvironment in lung cancer
- How do T lymphocytes decide their fate?
- How the epigenetic regulator SMCHD1 works and how to target it to treat disease
- Human lung protective immunity to tuberculosis: host-environment systems biology
- Human monoclonal antibodies against malaria infection
- Identifying novel treatment options for ovarian carcinosarcoma
- Inflammasome activation in autoinflammatory disease
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating microbial natural products with anti-protozoal activity
- Investigating the role of mutant p53 in cancer
- Investigating the role of platelets in motor neuron disease
- Mapping DNA repair networks in cancer
- Molecular mechanisms controlling embryonic lung progenitor cells
- Nanobodies against malaria
- Neutrophil heterogeneity in inflammation
- New approaches to treat cancer and inflammatory disease using the ubiquitin system
- Next generation CRISPR screens using iPSC
- Novel cell death and inflammatory modulators in lupus
- Programming T cells to defend against infections
- Restraining cytokine-receptor signalling in myeloproliferative neoplasms
- Screening for regulators of jumping genes
- Statistical analysis of genome-wide chromatin organisation using Hi-C
- Statistical analysis of trapped-ion-mobility time-of-flight mass spectrometry proteomics data
- Structure and function of E3 ubiquitin ligases
- Target identification of potent antimalarial agents
- The mitochondrial TOM complex in neurodegenerative disease
- The molecular mechanisms underlying Kir4.1 activity in gliomas
- The role of differential splicing in the genesis of breast cancer
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding malaria infection dynamics
- Understanding the function of the E3 ligase Parkin in Parkinson’s disease
- Understanding the molecular basis of chromosome instability in gastric cancer
- Utilising pre-clinical models to discover novel therapies for tuberculosis
- School resources
- Frequently asked questions
- Student profiles
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Bowel cancer

Australia has one of the highest rates of bowel cancer in the world. Each year, more than 16,000 Australians are diagnosed with bowel cancer. Many bowel cancers are detected at later, difficult to treat stages. If detected early, almost all cases of bowel cancer are curable. We are working to develop better early detection tests and to improve treatments for bowel cancer.

Understanding how these crypts and buds develop could help scientists understand what happens
when bowel cancer develops.
Our bowel cancer research
Our bowel cancer scientists and clinicians are working to improve the detection and treatment of bowel cancer by:
- Understanding the changes in healthy bowel cells that drive cancer formation.
- Deciphering how cancer cells 'communicate' with their environment to promote tumour growth.
- The role of bacterial infections and inflammation in cancer development.
- Developing better ways to detect and treat early-stage bowel cancer, including through a blood test.
- Discovering potential new treatments for bowel cancer.
- Matching people with bowel cancer to the best treatment for their disease.
What is bowel cancer?
Bowel cancer begins as an uncontrolled growth of cells in the walls of the bowel (the large intestine – the colon or the rectum). If untreated, the cancer can spread to other organs. Bowel cancer may also be called colon cancer or colorectal cancer.
Most bowel cancers arise from cells in the bowel lining called epithelial cells. These cells become cancerous after acquiring genetic changes that make them divide excessively and become long-lived.
Small non-cancerous growths in the bowel lining called ‘polyps’ often precede bowel cancer. Most polyps do not grow any further. Occasionally the cells in a polyp undergo changes that make them grow into a larger tumour. This can damage or block the bowel. ‘Metastatic’ or ‘secondary’ bowel cancer occurs when cancer cells spread beyond the bowel and travel to other parts of the body, where they grow as tumours.
Bowel development and cancer
Bowel cancers arise from the cells that line the bowel. They occur because the systems that normally control cell growth and survival have stopped working properly. Many processes that occur in bowel cancer cells are similar to those occurring during the development and growth of the bowel in embryos. Understanding how cell growth is controlled during bowel development is revealing what goes awry in bowel cancer.
Bowel cancer risk factors
Most bowel cancers arise ‘spontaneously’, with no predictable cause. Like many cancers, the risk of developing bowel cancer increases with age. About 92 per cent of people diagnosed with bowel cancer are over the age of 50.
Other risk factors for developing bowel cancer are:
- A history of developing polyps, or an earlier case of bowel, stomach or uterine cancer. These cancers may all be caused by similar cancer-causing gene abnormalities.
- Having relatives who had polyps or bowel cancer. People can be tested for inherited (familial) bowel cancer risk genes.
- Having inflammatory bowel disease, such as colitis or Crohn’s disease.
- A diet high in red meats, processed meats, fried foods or alcohol, or low in vegetables, fruit and whole grains.
- Being obese or physically inactive.
- Smoking.
How is bowel cancer detected?
The earliest, most treatable forms of bowel cancer generally have no symptoms. Clinical trials have shown that offering bowel cancer screening tests to people older than 50 years saves lives through early detection. Screening is a cost-effective way to detect bowel cancer at early and curable stages.
Currently, bowel cancer screening uses the faecal occult blood test (FOBT) that detects small amounts of blood in a stool (faeces) sample. Blood in stools is a possible sign of early bowel cancer.
When bowel cancer is suspected, the bowel lining can be examined by colonoscopy or sigmoidoscopy. In these, a flexible video camera is passed into the bowel through the anus. Samples from possible bowel cancer can be removed for microscopic diagnosis.
Some bowel cancers can also be detected using non-invasive imaging techniques such as ‘virtual colonoscopy’ or a magnetic resonance imaging (MRI) scan to create a three-dimensional image of the bowel. These techniques can miss polyps or small cancers that may be detected by colonoscopy and are currently considered inferior to a colonoscopy.
There is as yet no blood test that can reliably detect bowel cancer. Developing such a test is a goal of our bowel cancer researchers
For further information about bowel cancer detection please visit Bowel Cancer Australia.
How is bowel cancer treated?
Earlier diagnosis and better treatments have seen a doubling in survival rates from bowel cancer in Australia over the past 40 years.
When bowel cancer is detected early, before it has spread outside the bowel, it can often be cured by using surgery to remove the section of the bowel that contains the cancer.
When the cancer has spread outside the bowel (metastatic bowel cancer), surgery is usually combined with other treatments to kill any remaining cancer cells. Chemotherapy is an important part of treatment for metastatic bowel cancer. Several different chemotherapy drugs are used to treat bowel cancer, either alone or in combinations of two or more drugs.
Recently, some ‘monoclonal antibody’ treatments have been shown to be effective for treating bowel cancer. These contain antibodies that bind to proteins that are helping the bowel cancer to grow. This blocks the proteins’ function, preventing cancer growth. Monoclonal antibody treatments are sometimes combined with chemotherapy to increase their effect.
Bowel cancer treatment is currently hindered by a poor understanding of which patients will respond to which treatments. Genetic testing of bowel cancers is starting to reveal certain gene changes that predict whether a patient will respond well to a certain type of treatment. In particular, this testing can indicate whether monoclonal antibody treatments will be effective.
For more detailed information about bowel cancer treatment, please visit Bowel Cancer Australia.
Institute researchers are not able to provide specific medical advice specific to individuals. If you have bowel cancer and wish to find out more information about clinical trials, please visit Australian Cancer Trials or the Australian New Zealand Clinical Trials Registry, or consult your medical specialist.
Researchers:
Super Content:
Clinician scientists Associate Professor Jeanne Tie and Associate Professor Sumitra Ananda are leading trials of a blood test to guide cancer treatment after surgery.
Our research into bowel development has suggested a new mechanism for how bowel cancer starts.
A collaborative research effort has offered new hope for treating bowel cancer.
Dr Tracy Putoczki speaks with ABC Radio AM about her team's discovery of a new target for anti cancer therapies
Our research has demonstrated a potential new way to treat two of the most common cancers worldwide.